你即將離開本站

並前往https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibb-Research-at-ESMO-2021-Demonstrates-Clinical-Benefits-of-Immunotherapies-in-Multiple-Hard-to-Treat-Advanced-or-Metastatic-Cancers-and-Reinforces-the-Benefit-of-Opdivo-in-Earlier-Stage-Cancers/default.aspx

Bristol Myers Squibb Research at ESMO 2021 Demonstrates ...

“Our data at this year's ESMO show that Opdivo and Opdivo-based regimens, including combinations with our immune checkpoint inhibitor Yervoy and ...

確定！ 回上一頁

查詢 「ESMO」的人也找了：

  1. ESMO 2022
    2.
  2. ESMO Asia
    3.
  3. ESMO 2021
    4.
  4. esmo中文
    5.
  5. Gist esmo
    6.
  6. ESMO Asia 2021
    7.
  7. ESMO 2021 Abstract
    8.
  8. esmo歐洲
    9.